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Abstract
Background: Gonorrhea treatment has been complicated by antimicrobial resistance in Neisseria 
gonorrhoeae. Gonococcal fluoroquinolone resistance emerged more rapidly among men who have 
sex with men (MSM) than among men who have sex exclusively with women (MSW).
Objective: To determine whether N. gonorrhoeae urethral isolates from MSM were more likely 
than isolates from MSW to exhibit resistance to or elevated minimum inhibitory concentrations 
(MICs) of antimicrobials used to treat gonorrhea.
Design: Six years of surveillance data from the Gonococcal Isolate Surveillance Project (GISP)
Setting: Publicly-funded sexually transmitted disease clinics in 30 United States cities
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Patients: Men with a total of 34,600 episodes of symptomatic urethral gonorrhea
Measurements: Primary outcomes included percentage of isolates exhibiting resistance or 
elevated MICs, and adjusted odds ratios for resistance or elevated MICs among isolates from 
MSM compared to isolates from MSW.
Funding Source: GISP is funded by the CDC, an agency of the US Department of Health and 
Human Services.
Results: Isolates from MSM were significantly more likely than isolates from MSW to exhibit 
elevated cephalosporin MICs (P <=0.028). Isolates from MSM had a high prevalence of resistance 
to ciprofloxacin, penicillin, and tetracycline and were significantly more likely to exhibit 
antimicrobial resistance than isolates from MSW (P <0.001).
Limitations: Sentinel surveillance might not be representative of all patients with gonorrhea. 
HIV status, travel history, and antimicrobial use data were missing for some patients.
Conclusions: MSM are vulnerable to the emerging threat of multidrug-resistant N. gonorrhoeae. 
Because antimicrobial susceptibility testing is not routinely performed in clinical practice, 
clinicians should monitor for treatment failures among MSM diagnosed with gonorrhea. 
Strengthened prevention strategies for MSM and new antimicrobial treatment options are needed.
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Introduction
Gonorrhea, caused by Neisseria gonorrhoeae, is the second most commonly reported 
notifiable infection in the United States, with 309,341 cases reported in 2010. (1) Gonorrhea 
is associated with pelvic inflammatory disease, ectopic pregnancy, infertility, and 
epididymitis, and may facilitate HIV transmission. (2–5) Prevention of sequelae and control 
of disease transmission rely on prompt treatment with effective antimicrobial therapy.
The introduction of antimicrobial therapy in the 1930s ushered in an era of effective 
treatment options for gonorrhea. Yet N. gonorrhoeae rapidly developed resistance to 
sulfonamides and proved adept at developing resistance to each antimicrobial subsequently 
recommended for treatment: penicillin, tetracycline, and fluoroquinolones. Gonococcal 
resistance to penicillin and tetracycline developed both through the stepwise accumulation of 
chromosomal mutations and through acquisition of plasmids conferring high-level 
resistance.(6–9) Quinolone-resistant N. gonorrhoeae (QRNG) emerged in East Asia during 
the 1990s and subsequently spread to Hawaii, the Pacific Islands, and the US West Coast.
(10) In the US, the prevalence of QRNG initially rose rapidly among men who have sex with 
men (MSM) and by 2004, fluoroquinolones were no longer recommended for gonorrhea 
treatment in MSM.(11) Three years later, the Centers for Disease Control and Prevention 
(CDC) no longer recommended fluoroquinolones for treatment of gonorrhea in anyone in 
the US; third-generation cephalosporins were the only remaining recommended 
antimicrobial class.(12) CDC now recommends that gonorrhea be treated with combination 
antimicrobial therapy with ceftriaxone, an injectable cephalosporin, plus either azithromycin 
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or doxycycline as the only remaining first-line treatment options for gonorrhea.(13) Recent 
data indicating that cephalosporin (particularly cefixime) minimum inhibitory concentrations 
(MICs) for N. gonorrhoeae have increased in the US and are increasing rapidly among 
isolates from MSM are concerning.(13) The emergence of cephalosporin-resistant N. 
gonorrhoeae could greatly limit treatment options for gonorrhea.
In light of rapid emergence of QRNG among MSM and the current potential for emergence 
of cephalosporin-resistant N. gonorrhoeae, we investigated whether N. gonorrhoeae isolates 
from MSM were more likely than isolates from men who have sex exclusively with women 
(MSW) to exhibit elevated cephalosporin or azithromycin MICs or resistance to other 
antimicrobial classes previously recommended for treatment.
Methods
Data Source
We used data from the Gonococcal Isolate Surveillance Project (GISP), a national sentinel 
surveillance system that includes participating sexually transmitted disease (STD) clinics in 
US cities, reference laboratories, and the CDC. GISP was established in 1986 to monitor 
national trends in gonococcal antimicrobial susceptibilities. During 2005–2010, clinics in 30 
cities participated in GISP (Figure). Each month, N. gonorrhoeae urethral isolates were 
collected from the first 25 men with symptomatic gonococcal urethritis attending 
participating STD clinics in each city and the isolates were submitted to reference 
laboratories for antimicrobial susceptibility testing. Specified epidemiological data elements 
(see Statistical Analysis section below) were abstracted from STD clinic notes. Data 
collection methods varied according to local clinic practices.
Human Subjects
As a disease control and surveillance activity, GISP was determined to be a non-research 
public health activity by CDC. Gonorrhea is a notifiable infection and health departments 
have authority to collect and transmit to CDC de-identified epidemiological data on patients 
with gonorrhea to assist with disease control. Antimicrobial and epidemiologic data from 
GISP are de-identified prior to transmission to CDC. Partner identification and notification 
are conducted as per local STD public health program policies.
Laboratory Methods
At the clinic laboratories, the isolates were sub-cultured on supplemented chocolate medium 
and frozen in trypticase soy broth with 20% glycerol. Isolates were shipped monthly to a 
participating reference laboratory where they were tested for ß-lactamase production and 
susceptibility by MICs to azithromycin, penicillin, tetracycline, ciprofloxacin, 
spectinomycin, cefixime, and ceftriaxone using the agar-dilution technique. Standardized 
bacterial suspensions were inoculated on Difco GC base medium supplemented with 1% 
IsoVitalex (Becton-Dickinson, Sparks, Maryland). Cefixime susceptibility testing was halted 
in 2007 due to lack of availability of cefixime in the United States and restarted in 2009. 
Control N. gonorrhoeae strains with known MICs of a variety of antimicrobials were 
included with each susceptibility run to ensure accuracy of the data. Twice yearly, CDC 
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provided a panel of unidentified strains to each reference laboratory for testing; results were 
compared to assure inter-laboratory consistency.
Resistance criteria
We interpreted susceptibility results according to criteria for N. gonorrhoeae recommended 
by the Clinical and Laboratory Standards Institute (CLSI) when such criteria were available.
(14) We used CLSI criteria to define resistance to penicillin (MIC ≥ 2 μg/ml), tetracycline 
(MIC ≥ 2 μg/ml), and ciprofloxacin, a quinolone antimicrobial (MIC ≥ 1 μg/ml). CLSI 
defines decreased susceptibility to cephalosporins ceftriaxone and cefixime (MICs ≥ 0.5 
μg/ml) but does not define resistance. Increasing MICs can predict the emergence of 
resistance, so CDC uses lower MIC breakpoints, designated “elevated MICs”, to monitor 
trends in gonococcal susceptibility: ceftriaxone MICs ≥ 0.125 μg/ml and cefixime MICs ≥ 
0.25 μg/ml. The breakpoints chosen for the 2 cephalosporins differ because ceftriaxone 
MICs in GISP isolates are generally 1–2 dilutions lower than cefixime MICs (1). CLSI does 
not define gonococcal susceptibility nor resistance breakpoints for azithromycin. We 
categorized isolates with azithromycin MICs ≥ 2.0 μg/ml as exhibiting elevated MICs of 
azithromycin. We defined penicillinase-producing N. gonorrhoeae by positive results on the 
nitrocefin β-lactamase test. Where not otherwise specified, we considered penicillin 
resistance to include either chromosomal resistance (MIC ≥ 2.0 μg/ml and β-lactamase-
negative) or penicillinase-producing strains. We defined multidrug resistance as resistance to 
penicillin, tetracycline, and ciprofloxacin, and demonstration of elevated MICs of cefixime. 
We considered resistance phenotypes that have been prevalent in the US for ≥ 5 years, such 
as resistance to penicillin, tetracycline, and ciprofloxacin, to be “endemic,” and the other 
phenotypes to be “emerging”.
Statistical analysis
We included data from all cities that contributed to GISP during 2005–2010 and restricted 
the analytic sample to isolates for which we had data on gender of sex partner; we 
categorized men as either MSM or MSW. Gay and bisexual men were grouped together as 
MSM because we were interested in the possible association between resistance or elevated 
MICs and male same-sex sexual behavior, rather than self-identified sexual orientation. 
Clinical sites were categorized by US census region (Figure); the Northeast and South were 
combined due to the small number of sites in the Northeast and the history of similar timing 
of the emergence of resistance in the two regions. Gonococcal resistance in the United States 
tends to emerge initially in the West and spread eastward.(7, 10) Geographic region, age, 
race/ethnicity, HIV status, antimicrobial use in the past 60 days, prior gonococcal infection 
in the past 12 months, and travel outside of the state in which the isolate was collected in the 
past 60 days were pre-selected as potential confounders based on existing literature and 
biological plausibility. More detailed data about sexual behavior, such as the number of 
recent sex partners, are not routinely collected in GISP. To build a sustainable surveillance 
system, GISP attempts to minimize the data collection burden on sites and collect a small 
number of variables that can inform public health authorities about populations in which 
resistance may be emerging. We used the chi-square statistic to compare the frequency 
distributions of categorical variables. To evaluate the associations between antimicrobial 
resistance or elevated MICs and gender of sex partner after adjusting for potential 
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confounders, we constructed separate multivariable logistic regression models, with 
antimicrobial resistance or elevated MICs as the dependent variable for each antimicrobial 
agent. In each multivariable model for the resistance phenotypes, we included gender of sex 
partner, other variables mentioned above as potential confounders, and the pre-specified 
interaction between gender of sex partner and geographic region. Missing values for HIV 
infection, travel history, antimicrobial use, and prior gonococcal infection were imputed 
using the logistic regression method in Proc MI from SAS 9.3. We generated 5 imputed 
datasets using this procedure and used the multivariable logistic regression method in Proc 
MIANALYZE to analyze these datasets. All statistical analyses were conducted using SAS, 
version 9.3 (SAS Institute, Cary, North Carolina).
Sensitivity Analyses
We performed sensitivity analyses in which missing values were handled two different ways. 
In the first method, we excluded observations with missing data and repeated the analyses. 
For the second method, we considered all missing values for HIV infection, travel history, 
antimicrobial use, and prior gonococcal infection to be negative and repeated the analyses. 
Results of these sensitivity analyses are available in the Appendix, Table B.
Because of small numbers of individuals with resistance or elevated MICs for azithromycin, 
cefixime, ceftriaxone, and multidrug resistance, we also constructed simple models to assess 
the relationship between gender of sex partner and emerging resistance phenotypes. In these 
models, we used antimicrobial resistance or elevated MICs as the dependent variable for 
each antimicrobial agent and only gender of sex partner, region, and the pre-specified 
interaction between gender of sex partner and geographic region as independent variables. 
Results of these sensitivity analyses are available in the Appendix, Table C.
Funding Source
GISP is funded by the CDC, an agency of the US Department of Health and Human 
Services. CDC staff were involved in the design and conduct of this surveillance activity and 
the collection, management, analysis, and interpretation of GISP data.
Results
During 2005–2010, 35,343 isolates were collected from men in 30 cities (range per year: 
5,630–6,199). This represents approximately 4% of all reported male gonorrhea cases in the 
US. Gender of sex partner data were available for 34,600 (97.9%) isolates: 8,117 (23.5%) 
were from MSM and 26,483 (76.5%) were from MSW. MSM were older than MSW, and 
more likely to be white and from the Western region of the US (Table 1). Prior N. 
gonorrhoeae infection, antimicrobial use, HIV infection, and recent travel were more 
frequent among MSM than MSW (P < 0.001). After stratifying by HIV status, MSM were 
still more likely to report recent antimicrobial use (for HIV-infected men: 15.0% in MSM 
versus 9.0% in MSW, P=0.017; for HIV-uninfected: 6.9% in MSM versus 5.0% in MSW, P 
<0.001). Isolates from MSM exhibited significantly (P <0.001) higher prevalence of 
resistance to or elevated MICs of each antimicrobial class, including cephalosporins, than 
isolates from MSW (Table 1).
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Tables 2A and2B display adjusted odds ratios for resistance or elevated MICs among 
isolates from MSM compared to isolates from MSW, both for emerging resistance 
phenotypes (azithromycin, cefixime, ceftriaxone, and multidrug resistance) and endemic 
resistance phenotypes (ciprofloxacin, penicillin, and tetracycline). Interaction effects by 
region are shown and indicate significant differences by region in the magnitude of the 
association between resistance/elevated MICs and gender of sex partner. The displayed 
results are the adjusted odds ratios of elevated MICs or resistance among isolates from MSM 
compared to isolates from MSW, for each specific region. For example, isolates from MSM 
in the West had 1.4 times greater odds of elevated azithromycin MICs than isolates from 
MSW in the West (although the difference was non-significant), whereas isolates from MSM 
in the Midwest had 7.9 times greater odds of elevated azithromycin MICs than isolates from 
MSW in the Midwest. Isolates from MSM were significantly more likely than isolates from 
MSW to exhibit elevated cefixime MICs, antimicrobial resistance to penicillin, tetracycline, 
and ciprofloxacin, and multidrug resistance, after adjusting for other covariates. In the 
Midwestern and Northeastern/Southern regions of the United States (but not the Western 
region), isolates from MSM were significantly more likely than isolates from MSW to 
exhibit elevated MICs of azithromycin or ceftriaxone. Complete results of the models are 
shown in appendix Table A.
Sensitivity analyses were performed to evaluate the effect of different approaches for 
handling missing data on the results displayed in Table 2B. The results obtained by 
excluding missing data or considering missing data to be negative were consistent with the 
primary analysis (Appendix, Table B). Results of the simple models examining the 
association between elevated MICs of azithromycin, cefixime, or ceftriaxone, or multidrug 
resistance and gender of sex partner, adjusted for region and the interaction of gender of sex 
partner & region, were consistent with the results of the primary analysis (Appendix, Table 
C).
Discussion
During the past seventy years, N. gonorrhoeae has developed resistance over time to 
antimicrobial agents recommended for the treatment of gonorrhea. Combination therapy 
with ceftriaxone (a third-generation cephalosporin) and either azithromycin or doxycycline 
is now the only remaining first-line therapeutic option.(13) However, gonococcal 
susceptibility to cephalosporins, the cornerstone of treatment, is declining. Failures of 
treatment with oral cephalosporins have been reported in Asia and Europe in the past several 
years and ceftriaxone-resistant isolates were identified in Japan in 2009 and France in 2010.
(15–20) In the US, MICs of cefixime for N. gonorrhoeae increased during 2006–2010, most 
notably in the West and among MSM.(13) In addition, gonococcal strains with high 
azithromycin MICs have been identified in the US (21, 22) and a patient unsuccessfully 
treated with azithromycin 2 g as a single oral dose was recently identified.(23) The 
introduction and spread of cephalosporin-resistant N. gonorrhoeae, particularly if also 
exhibiting azithromycin resistance, would greatly limit treatment options for gonorrhea and 
could render some cases of gonorrhea untreatable with currently recommended drug 
regimens.
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MSM are particularly vulnerable to this emerging public health threat. In geographic areas 
participating in the STD Surveillance Network, approximately 22% of reported gonorrhea 
cases occur in MSM, although with substantial geographic variability (CDC, unpublished 
data). Previously published reports have described a higher prevalence of resistance to or 
elevated MICs of individual antimicrobials among isolates from MSM (11,13,24,25), but 
this is the first report to describe such findings across a range of antimicrobial classes either 
currently or previously recommended for gonorrhea treatment.
During the emergence of QRNG in the US, the prevalence of QRNG increased more rapidly 
among MSM than MSW: from 2002 to 2003, the prevalence of QRNG increased among 
MSM from 1.8% to 4.9%, but only from 0.2% to 0.4% among MSW.(11) By 2004, CDC no 
longer recommended fluoroquinolones for treatment of gonorrhea among MSM, three years 
before the same change in recommendation was made for heterosexuals.(12) The prevalence 
of QRNG remains high among MSM, despite the change in treatment recommendations and 
decline in fluoroquinolone use for gonorrhea.(26) A similar pattern seems to be emerging for 
cephalosporins, as MICs of cephalosporins are increasing more rapidly among MSM than 
MSW in the US and United Kingdom.(13,27)
Antimicrobial resistance in other clinically important microbes has also been described more 
often for MSM than for MSW. In a sample of recently diagnosed HIV-1 infected persons 
enrolled during 1997–2001, the prevalence of antiretroviral resistance associated mutations 
was significantly higher among MSM (11.6%) than among MSW (4.7%), possibly due to 
greater exposure to antiretroviral therapy.(28) MSM have been noted to be at elevated risk 
for community-associated methicillin-resistant Staphylococcus aureus, and an outbreak of 
ciprofloxacin-resistant Shigella sonnei among MSM has been described.(29,30)
The causes of the differences in gonococcal antimicrobial susceptibility between MSM and 
MSW are not fully understood, but there are several possible explanations. First, MSM 
might be more likely to travel internationally: a high proportion of newly HIV-infected 
MSM in San Francisco reported recent international travel or foreign-born sex partners.(31) 
This may be relevant because some cases of penicillinase-producing N. gonorrhoeae and 
QRNG appeared to have been imported into the US in the past by travelers from East Asia.
(7, 32) Second, events such as circuit parties may provide a nexus for sexual interaction 
among MSM from different geographic regions (33) and potentially facilitate spread of 
resistant strains among MSM in different geographic regions. Third, we found that MSM 
with gonorrhea were more likely than MSW to report antimicrobial use in the past 60 days, 
possibly resulting in greater antimicrobial selection pressure. Although this might not 
explain the emergence of a resistance phenotype, which may be imported from other regions 
of the world, differential antimicrobial use might contribute to the selection and persistence 
of resistance phenotypes in the US. Fourth, N. gonorrhoeae infections of the rectum and/or 
pharynx might be more prone to develop antimicrobial resistance than urogenital isolates; 
resistant gonococcal strains may thus have a selective advantage for survival in and 
transmission to and from these sites in MSM. Rectal isolates have been noted to have higher 
geometric mean MICs of penicillin and erythromycin than genital isolates, possibly due to 
mutations in the mtr locus that result in reduced outer membrane permeability to 
hydrophobic molecules that allow the organism to survive in the rectum.(24,25,34–36) It has 
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also been hypothesized that genetic re-assortment in pharyngeal infections might contribute 
to cephalosporin resistance: mosaic penA mutants found in many N. gonorrhoeae isolates 
with decreased susceptibility to cefixime include genetic material from commensal Neisseria 
species often found in the pharynx.(37) Under-treatment of pharyngeal gonorrhea, which is 
difficult to eradicate and often asymptomatic, could also select for resistance. It thus might 
not be a coincidence that the recently described ceftriaxone-resistant isolate from Japan was 
isolated from the pharynx of a female commercial sex worker.(19)
Cephalosporins MICs increased earlier and more steeply in the West than other regions (13). 
However, the adjusted odds ratios of elevated cephalosporins MICs among isolates from 
MSM compared to MSW are consistently lower than for other regions. This seeming 
contradiction is most likely due to the early increase in MICs in the West, which started in 
MSM and are now also observed in MSW, thus decreasing the magnitude of the association.
This analysis has several limitations. An increasing proportion of cases of gonorrhea are 
diagnosed and reported from clinical settings other than public STD clinics.(1) Thus, it is 
possible that our results may not be representative of all men with gonorrhea in the US. 
However, this is unlikely to alter the relative differences in resistance patterns between 
isolates from MSM and MSW. The analysis aggregated gay and bisexual men as MSM. 
Further work could investigate possible differences between isolates from gay and bisexual 
men. The aggregation of isolates from the Northeast and South may mask finer differences 
in susceptibility by geographic locations. However, as a sentinel surveillance system, GISP 
cannot and is not designed to provide full geographic coverage. The breakpoints for 
cephalosporin susceptibility that we used in this analysis do not necessarily represent 
“clinical” resistance. However, it is likely that increasing cephalosporin MICs will precede 
the emergence of resistance, and resistance would emerge first in the populations infected 
with strains exhibiting increasing MICs. GISP does not collect detailed behavioral data. 
Further work could investigate whether specific antimicrobial usage patterns or sexual 
behaviors, such as the number of recent partners or the type of sex in which men engaged 
(e.g. insertive versus receptive), influence gonococcal antimicrobial susceptibility. A 
substantial proportion of antimicrobial use, HIV, and travel history data were missing 
because some participating sites do not collect these data routinely. For instance, over 40% 
of travel data were missing. However, the results of the sensitivity analyses suggest that 
substantial bias was not introduced by missing data.
Strengthening prevention strategies for MSM is critical in this era of dwindling treatment 
options. The number of antimicrobials newly approved by the FDA has steadily declined,
(38) and few new antimicrobials active against N. gonorrhoeae are being developed. New 
antimicrobials or antimicrobial combinations need to be developed and existing 
antimicrobials not yet used for gonorrhea should be evaluated for efficacy. The National 
Institute for Allergy and Infectious Diseases, in collaboration with CDC, has completed 
enrollment of a clinical trial of 2 combinations of existing drugs: azithromycin plus either 
gentamicin or gemifloxacin (NCT00926796). But additional antimicrobial agents should be 
studied. Clinicians are encouraged to screen sexually active MSM at all anatomic sites of 
exposure at least annually (39) and to treat those diagnosed with gonorrhea with ceftriaxone 
250 mg as a single intramuscular dose plus either azithromycin 1 g orally or doxycycline 
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100 mg twice daily orally for 7 days.(13) Clinicians must remain vigilant for treatment 
failures, even among patients treated with recommended therapy, and should notify their 
local or state health department and CDC of possible treatment failures. Continued 
surveillance of N. gonorrhoeae antimicrobial susceptibility, particularly among MSM, is 
vital. Local surveillance can be enhanced by the maintenance or establishment of laboratory 
capacity to conduct culture for N. gonorrhoeae, a capacity lost in many places due to the 
widespread use of nucleic acid amplification testing. Sexually active MSM are encouraged 
to be in long-term mutually monogamous relationships with partners who have been tested 
and are known to be uninfected. Latex condoms, when used consistently and correctly, can 
reduce the risk of acquiring gonorrhea.(40)
The emergence of cephalosporin-resistant Neisseria gonorrhoeae would substantially 
complicate the ability to treat gonorrhea. MSM at risk for gonorrhea are particularly 
vulnerable to this public health threat.
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Figure 1. 
Gonococcal lsolate surveillance Project (GISP) —Location of Participating Sentinel Sites 
and Regional Laboratories,united states,2005–2010*
*Sites had continuous participation during 2005–2010 with the following exceptions (and 
years of participation): Kansas City (2007–2010); Long Beach (2005–2007); New York City 
(2006–2010); Richmond (2007–2010); Tripler AMC(2006, 2009–2010)
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Table 2A.
Adjusted odds ratios of emerging Neisseria gonorrhoeae antibiotic resistance or elevated MICs among MSM 
compared to MSW, GISP, 2005–2010
Emerging Resistance
Variable aOR 95% CI
Azithromycin, elevated MICs*
West 1.4 0.8–2.2
Midwest 7.9 3.0–21.1
Northeast/South 3.7 1.3–10.5
Cefixime, elevated MICs†
West 2.7 1.7–4.4
Midwest 12.9 3.8–43.7
Northeast/South 33.1 3.8–286.4
Ceftriaxone, elevated MICs‡
West 1.3 0.6–3.0
Midwest 6.8 2.2–20.6
Northeast/South 3.6 1.1–11.0
Multidrug resistance§
West 2.6 1.5–4.7
Midwest 57.1 7.1–471.8
Northeast/South 36.4 4.2–315.5
aOR = adjusted odds ratio; CI = confidence interval;
GISP = the Gonococcal Isolate Surveillance Project;
MIC = minimum inhibitory concentration; MSM = men
who have sex with men; MSW = men who report
having sex exclusively with women
All models adjusted for age, region, race/ethnicity, antimicrobial use, travel history, HIV infection, prior gonococcal infection, and the interaction 
between gender of sex partner & region.
*
MIC ≥ 2 μg/ml
†
MIC ≥ 0.25 μg/ml
‡
MIC ≥ 0.125 μg/ml
§
Penicillin MICs ≥ 2 μg/ml or β-lactamase positive, tetracycline MICs ≥ 2 μg/ml, ciprofloxacin MICs ≥1 μg/ml, and cefixime MICs ≥ 0.25 μg/ml
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Table 2B.
Adjusted odds ratios of endemic Neisseria gonorrhoeae antibiotic resistance among MSM compared to MSW, 
GISP, 2005–2010
  Endemic Resistance
Variable aOR 95% CI
Ciprofloxacin, resistance║
West 2.6 2.4–2.9
Midwest 10.8 8.4–13.9
Northeast/South 2.5 2.2–2.9
Penicillin, resistance¶
West 2.1 1.9–2.4
Midwest 4.0 3.2–5.0
Northeast/South 2.3 2.0–2.6
Tetracycline, resistance#
West 2.5 2.3–2.8
Midwest 5.4 4.5–6.4
Northeast/South 2.1 1.9–2.4
aOR = adjusted odds ratio; CI = confidence interval;
GISP = the Gonococcal Isolate Surveillance Project;
MIC = minimum inhibitory concentration; MSM = men
who have sex with men; MSW = men who report
having sex exclusively with women
All models adjusted for age, region, race/ethnicity, antimicrobial use, travel history, HIV infection, prior gonococcal infection, and the interaction 
between gender of sex partner & region.
║
MIC ≥ 1 μg/ml
¶
MIC ≥ 2 μg/ml or β-lactamase positive
#
MIC ≥ 2 μg/ml
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